NEW YORK, Nov. 28, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning,
Market Source Research released its latest key findings for all current investors, traders, and shareholders of Bellicum
Pharmaceuticals, Inc. (NASDAQ:BLCM), NetEase, Inc. (NASDAQ:NTES), Nice Ltd. (NASDAQ:NICE), Match Group, Inc. (NASDAQ:MTCH),
SpartanNash Company (NASDAQ:SPTN), and Adaptimmune Therapeutics PLC (NASDAQ:ADAP), including updated fundamental summaries,
consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
BLCM DOWNLOAD: http://MarketSourceResearch.com/register/?so=BLCM
NTES DOWNLOAD: http://MarketSourceResearch.com/register/?so=NTES
NICE DOWNLOAD: http://MarketSourceResearch.com/register/?so=NICE
MTCH DOWNLOAD: http://MarketSourceResearch.com/register/?so=MTCH
SPTN DOWNLOAD: http://MarketSourceResearch.com/register/?so=SPTN
ADAP DOWNLOAD: http://MarketSourceResearch.com/register/?so=ADAP
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Market Source Research, available for free download at the links above, examine
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), NetEase, Inc. (NASDAQ:NTES), Nice Ltd. (NASDAQ:NICE), Match Group, Inc.
(NASDAQ:MTCH), SpartanNash Company (NASDAQ:SPTN), and Adaptimmune Therapeutics PLC (NASDAQ:ADAP) on a fundamental level and
outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management
discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's
readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone
summaries and as such, important information may be missing from these samples. Please download the entire research report, free of
charge, to ensure you are reading all relevant material information. All information in this release was accessed November 26th,
2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
BELLICUM PHARMACEUTICALS, INC. (BLCM) REPORT OVERVIEW
Bellicum Pharmaceuticals' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Bellicum Pharmaceuticals reported
revenue of $0.29MM vs $0.13MM (up 131.75%) and analysts estimated basic earnings per share -$0.55 vs -$0.71. For the twelve months
ended December 31st, 2017 vs December 31st, 2016, Bellicum Pharmaceuticals reported revenue of $0.19MM vs $0.39MM (down 52.32%) and
analysts estimated basic earnings per share -$2.89 vs -$2.57. Analysts expect earnings to be released on March 12th, 2019. The
report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.61. The
estimated EPS forecast for the next fiscal year is -$2.06 and is expected to report on March 12th, 2019.
To read the full Bellicum Pharmaceuticals, Inc. (BLCM) report, download it here: http://MarketSourceResearch.com/register/?so=BLCM
-----------------------------------------
NETEASE, INC. (NTES) REPORT OVERVIEW
NetEase's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, NetEase reported revenue of $2,454.18MM
vs $1,875.43MM (up 30.86%) and analysts estimated basic earnings per share $1.81 vs $2.88 (down 37.15%). For the twelve months
ended December 31st, 2017 vs December 31st, 2016, NetEase reported revenue of $8,315.33MM vs $5,498.90MM (up 51.22%) and analysts
estimated basic earnings per share $12.50 vs $12.73 (down 1.81%). Analysts expect earnings to be released on February 6th, 2019.
The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $1.49. The
estimated EPS forecast for the next fiscal year is $8.93 and is expected to report on February 6th, 2019.
To read the full NetEase, Inc. (NTES) report, download it here: http://MarketSourceResearch.com/register/?so=NTES
-----------------------------------------
NICE LTD. (NICE) REPORT OVERVIEW
Nice's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Nice reported revenue of $356.21MM vs
$322.76MM (up 10.36%) and analysts estimated basic earnings per share $0.64 vs $0.43 (up 48.84%). For the twelve months ended
December 31st, 2017 vs December 31st, 2016, Nice reported revenue of $1,332.15MM vs $1,015.54MM (up 31.18%) and analysts estimated
basic earnings per share $2.37 vs $1.96 (up 20.92%). Analysts expect earnings to be released on February 21st, 2019. The report
will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $1.27. The estimated EPS
forecast for the next fiscal year is $4.43 and is expected to report on February 21st, 2019.
To read the full Nice Ltd. (NICE) report, download it here: http://MarketSourceResearch.com/register/?so=NICE
-----------------------------------------
MATCH GROUP, INC. (MTCH) REPORT OVERVIEW
Match Group's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Match Group reported revenue of
$443.94MM vs $343.42MM (up 29.27%) and basic earnings per share $0.47 vs $1.08 (down 56.48%). For the twelve months ended December
31st, 2017 vs December 31st, 2016, Match Group reported revenue of $1,330.66MM vs $1,118.11MM (up 19.01%) and analysts estimated
basic earnings per share $1.33 vs $0.68 (up 95.59%). Analysts expect earnings to be released on February 5th, 2019. The report will
be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.25. The estimated EPS
forecast for the next fiscal year is $1.57 and is expected to report on February 5th, 2019.
To read the full Match Group, Inc. (MTCH) report, download it here: http://MarketSourceResearch.com/register/?so=MTCH
-----------------------------------------
SPARTANNASH COMPANY (SPTN) REPORT OVERVIEW
SpartanNash's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, SpartanNash reported revenue of
$1,886.73MM vs $1,868.40MM (up 0.98%) and analysts estimated basic earnings per share $0.49 vs -$3.32. For the twelve months ended
December 31st, 2017 vs December 31st, 2016, SpartanNash reported revenue of $8,128.08MM vs $7,734.60MM (up 5.09%) and analysts
estimated basic earnings per share -$1.41 vs $1.52. Analysts expect earnings to be released on February 20th, 2019. The report will
be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.41. The estimated EPS
forecast for the next fiscal year is $2.04 and is expected to report on February 20th, 2019.
To read the full SpartanNash Company (SPTN) report, download it here: http://MarketSourceResearch.com/register/?so=SPTN
-----------------------------------------
ADAPTIMMUNE THERAPEUTICS PLC (ADAP) REPORT OVERVIEW
Adaptimmune Therapeutics' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Adaptimmune Therapeutics reported
revenue of $40.79MM vs $27.19MM (up 50.05%) and analysts estimated basic earnings per share $0.06 vs -$0.01. For the twelve months
ended December 31st, 2017 vs December 31st, 2016, Adaptimmune Therapeutics reported revenue of $37.83MM vs $14.20MM (up 166.47%)
and analysts estimated basic earnings per share -$0.78 vs -$1.02. Analysts expect earnings to be released on March 21st, 2019. The
report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.29. The
estimated EPS forecast for the next fiscal year is -$1.23 and is expected to report on March 21st, 2019.
To read the full Adaptimmune Therapeutics PLC (ADAP) report, download it here: http://MarketSourceResearch.com/register/?so=ADAP
-----------------------------------------
ABOUT MARKET SOURCE RESEARCH
Market Source Research delivers the key research reports that helps serious investors, registered brokers,
professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team
is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA®
BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source
Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on
individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well
as granular detail.
REGISTERED MEMBER STATUS
Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes
qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers.
Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside
audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries
regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by
E-mail at compliance@MarketSourceResearch.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source
Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that
result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness
of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated
for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial
advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration.
For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Hugo Moreau, Media Department
Office: +1 (704) 343-6361
E-mail: media@MarketSourceResearch.com
© 2018 Market Source Research. All Rights Reserved. For republishing permissions, please contact a
partner network manager at partnership@MarketSourceResearch.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority,
Inc.
